Alembic rides generic Abilify wave amid compliance wins
This article was originally published in Scrip
Executive Summary
Shares of Alembic Pharmaceuticals surged on Indian bourses, after the US FDA cleared the first set of generic versions of Otsuka's schizophrenia and bipolar disorder drug Abilify (aripiprazole).